Physician profile
Patrick R Smith
NPI 1497086698
$2,975.79
in general payments reported to CMS, 2019-2025
16 companies · $2,026 in 2025
The $2,026 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $142 · 2024: $807 · 2025: $2,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,246 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $700 · Education: $29.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.00 |
| Education | $29.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,168.63 | 2024-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $488.13 | 2024-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Inari Medical, INC. | $267.53 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $252.56 | 2024-2025 | |
| Inspire Medical Systems, INC. | $186.20 | 2024-2025 | Inspire |
| Abiomed | $115.81 | 2025 | |
| Insmed, INC. | $112.79 | 2024-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $100.98 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $52.21 | 2025 | Glassia |
| Amgen INC. | $51.26 | 2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.93 | 2024-2025 | Ofev |
| Merck Sharp & Dohme LLC | $36.87 | 2024-2025 | Winrevair |
| United Therapeutics Corporation | $33.75 | 2024 | Remodulin |
| Bayer Healthcare Pharmaceuticals INC. | $29.01 | 2025 | |
| Tactile Systems Technology INC | $16.44 | 2025 | Flexitouch Plus, Nimbl |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $14.69 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.